nabilone and Body-Weight

nabilone has been researched along with Body-Weight* in 2 studies

Trials

1 trial(s) available for nabilone and Body-Weight

Article	Year
Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial. The Annals of otology, rhinology, and laryngology, 2016, Volume: 125, Issue:4 Patients treated for head and neck carcinomas experience a significant deterioration of their quality of life during treatments because of severe side effects. Nabilone has many properties that could alleviate symptoms caused by radiotherapy and improve patients' quality of life. The aim of the present study was to compare the effects of nabilone versus placebo on the quality of life and side effects during radiotherapy for head and neck carcinomas.. Fifty-six patients were randomized to nabilone or placebo. Patients filled the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-H&N35; three independent questionnaires assessing appetite, nausea, and toxicity; and a visual analog scale for pain. These data were collected before radiotherapy, each week during radiotherapy, and 4 weeks after radiotherapy. Patients were weighed every week.. Nabilone did not lengthen the time necessary for a 15% deterioration of quality of life (P = .4279), and it was not better than placebo for relieving symptoms like pain (P = .6048), nausea (P = .7105), loss of appetite (P = .3295), weight (P = .1454), mood (P = .3214), and sleep (P = .4438).. At the dosage used, nabilone was not potent enough to improve the patients' quality of life over placebo. Topics: Affect; Antiemetics; Appetite; Body Weight; Carcinoma, Squamous Cell; Chemoradiotherapy; Double-Blind Method; Dronabinol; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nausea; Pain; Pain Measurement; Quality of Life; Radiotherapy; Sleep; Squamous Cell Carcinoma of Head and Neck	2016

Article

Year

Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial.

The Annals of otology, rhinology, and laryngology, 2016, Volume: 125, Issue:4

Patients treated for head and neck carcinomas experience a significant deterioration of their quality of life during treatments because of severe side effects. Nabilone has many properties that could alleviate symptoms caused by radiotherapy and improve patients' quality of life. The aim of the present study was to compare the effects of nabilone versus placebo on the quality of life and side effects during radiotherapy for head and neck carcinomas.. Fifty-six patients were randomized to nabilone or placebo. Patients filled the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-H&N35; three independent questionnaires assessing appetite, nausea, and toxicity; and a visual analog scale for pain. These data were collected before radiotherapy, each week during radiotherapy, and 4 weeks after radiotherapy. Patients were weighed every week.. Nabilone did not lengthen the time necessary for a 15% deterioration of quality of life (P = .4279), and it was not better than placebo for relieving symptoms like pain (P = .6048), nausea (P = .7105), loss of appetite (P = .3295), weight (P = .1454), mood (P = .3214), and sleep (P = .4438).. At the dosage used, nabilone was not potent enough to improve the patients' quality of life over placebo.

Topics: Affect; Antiemetics; Appetite; Body Weight; Carcinoma, Squamous Cell; Chemoradiotherapy; Double-Blind Method; Dronabinol; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nausea; Pain; Pain Measurement; Quality of Life; Radiotherapy; Sleep; Squamous Cell Carcinoma of Head and Neck

2016

Other Studies

1 other study(ies) available for nabilone and Body-Weight

Article	Year
Effect of the synthetic cannabinoid nabilone on spermatogenesis in mice. Experientia, 1990, Aug-15, Volume: 46, Issue:8 Chronic treatment of mice with the synthetic cannabinoid nabilone (50 mg/kg, 3 times per week) reduced the number of pachytene spermatocytes. Nabilone did not affect other cell types in the testis or the sex organ weights. Nabilone tended to increase the number of abnormal spermatozoa, but this did not reach statistical significance. It is concluded that nabilone causes less testicular toxicity than the natural cannabinoids. Topics: Animals; Body Weight; Dronabinol; Male; Mice; Mice, Inbred Strains; Organ Size; Spermatocytes; Spermatogenesis; Testis	1990

Article

Year

Effect of the synthetic cannabinoid nabilone on spermatogenesis in mice.

Experientia, 1990, Aug-15, Volume: 46, Issue:8

Chronic treatment of mice with the synthetic cannabinoid nabilone (50 mg/kg, 3 times per week) reduced the number of pachytene spermatocytes. Nabilone did not affect other cell types in the testis or the sex organ weights. Nabilone tended to increase the number of abnormal spermatozoa, but this did not reach statistical significance. It is concluded that nabilone causes less testicular toxicity than the natural cannabinoids.

Topics: Animals; Body Weight; Dronabinol; Male; Mice; Mice, Inbred Strains; Organ Size; Spermatocytes; Spermatogenesis; Testis

1990